MedPage Today on MSN1d
Diabetes Study's Funding Yanked; Marriage-Obesity Link; CVS 'Menopause-Friendly'
Researchers for the ongoing 30-year Diabetes Prevention Program found out last week that the NIH canceled funding for the ...
pharmaphorum3d
Intercept hit hard as NASH trial misses the mark
Intercept Pharma's hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the ...
pharmaphorum1d
Intercept will have to face FDA advisors for NASH drug
Intercept Pharma’s obeticholic acid (OCA) – trying to become the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH) – will come under scrutiny by FDA advisors before the ...